Open AccessClinical and Economic Benefits of Lenzilumab Plus Standard of Care Compared with Standard of Care Alone for the Treatment of Hospitalized Patients with Coronavirus Disease 19 (COVID-19) from the Perspective of National Health Service England
Author(s) -
Adrian Kilcoyne,
E. O. Jordan,
Kimberly Thomas,
Alicia N. Pepper,
Allen S. Zhou,
Dale Chappell,
Miyuru Amarapala,
Rachel-Karson Thériault,
Melissa L. Thompson Bastin
Publication year - 2022
Publication title -
clinicoeconomics and outcomes research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.591
H-Index - 27
ISSN - 1178-6981
DOI - 10.2147/ceor.s360741
Subject(s) - medicine , covid-19 , standard of care , coronavirus , intensive care medicine , perspective (graphical) , disease , pandemic , virology , outbreak , infectious disease (medical specialty) , artificial intelligence , computer science
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom